CoChat

Progesterone receptor modulators for endometriosis

Open access
Fu, Jing, Song, Hao, Zhou, Min, Zhu, Huili, Wang, Yuhe, Chen, Hengxi, Huang, Wei · 2017 · Cochrane Database of Systematic Reviews
Cited by 61

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Endometriosis is defined as the presence of endometrial tissue (glands and stroma) outside the uterine cavity. This condition is oestrogen-dependent and thus is seen primarily during the reproductive years. Owing to their antiproliferative effects in the endometrium, progesterone receptor modulators (PRMs) have been advocated for treatment of endometriosis. OBJECTIVES: To assess the effectiveness and safety of PRMs primarily in terms of pain relief as compared with other treatments or placebo or no treatment in women of reproductive age with endometriosis. SEARCH METHODS: We searched the following electronic databases, trial registers, and websites: the Cochrane Gynaecology and Fertility Group (CGFG) Specialised Register of Controlled Trials, the Central Register of Studies Online (CRSO), MEDLINE, Embase, PsycINFO, clinicaltrials.gov, and the World Health Organization (WHO) platform, from inception to 28 November 2016. We handsearched reference lists of articles retrieved by the search. SELECTION CRITERIA: We included randomised controlled trials (RCTs) published in all languages that examined effects of PRMs for treatment of symptomatic endometriosis. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures as expected by the Cochrane Collaboration. Primary outcomes included measures of pain and side effects. MAIN RESULTS: We included 10 randomised controlled trials (RCTs) with 960 women. Two RCTs compared mifepristone versus placebo or versus a different dose of mifepristone, one RCT compared asoprisnil versus placebo, one compared ulipristal versus leuprolide acetate, and four compared gestrinone versus danazol, gonadotropin-releasing hormone (GnRH) analogues, or a different dose of gestrinone. The quality of evidence ranged from high to very low. The main limitations were serious risk of bias (associated with poor reporting of methods and high or unclear rates of attrition in most studies), very serious imprecision (associated with low event rates and wide confidence intervals), and indirectness (outcome assessed in a select subgroup of participants). Mifepristone versus placebo One study made this comparison and reported rates of painful symptoms among women who reported symptoms at baseline.At three months, the mifepristone group had lower rates of dysmenorrhoea (odds ratio (OR) 0.08, 95% confidence interval (CI) 0.04 to 0.17; one RCT, n =352; moderate-quality evidence), suggesting that if 40% of women taking placebo experience dysmenorrhoea, then between 3% and 10% of women taking mifepristone will do so. The mifepristone group also had lower rates of dyspareunia (OR 0.23, 95% CI 0.11 to 0.51; one RCT, n = 223; low-quality evidence). However, the mifepristone group had higher rates of side effects: Nearly 90% had amenorrhoea and 24% had hot flushes, although the placebo group reported only one event of each (1%) (high-quality evidence). Evidence was insufficient to show differences in rates of nausea, vomiting, or fatigue, if present. Mifepristone dose comparisons Two studies compared doses of mifepristone and found insufficient evidence to show differences between different doses in terms of effectiveness or safety, if present. However, subgroup analysis of comparisons between mifepristone and placebo suggest that the 2.5 mg dose may be less effective than 5 mg or 10 mg for treating dysmenorrhoea or dyspareunia. Gestrinone comparisons Ons study compared gestrinone with danazol, and another study compared gestrinone with leuprolin.Evidence was insufficient to show differences, if present, between gestrinone and danazol in rate of pain relief (those reporting no or mild pelvic pain) (OR 0.71, 95% CI 0.33 to 1.56; two RCTs, n = 230; very low-quality evidence), dysmenorrhoea (OR 0.72, 95% CI 0.39 to 1.33; two RCTs, n = 214; very low-quality evidence), or dyspareunia (OR 0.83, 95% CI 0.37 to 1.86; two RCTs, n = 222; very low-quality evidence). The gestrinone group had a higher rate of hirsutism (OR 2.63, 95% CI 1.60 to 4.32; two RCTs, n = 302; very low-quality evidence) and a lower rate of decreased breast size (OR 0.62, 95% CI 0.38 to 0.98; two RCTs, n = 302; low-quality evidence). Evidence was insufficient to show differences between groups, if present, in rate of hot flushes (OR 0.79, 95% CI 0.50 to 1.26; two RCTs, n = 302; very low-quality evidence) or acne (OR 1.45, 95% CI 0.90 to 2.33; two RCTs, n = 302; low-quality evidence).When researchers compared gestrinone versus leuprolin through measurements on the 1 to 3 verbal rating scale (lower score denotes benefit), the mean dysmenorrhoea score was higher in the gestrinone group (MD 0.35 points, 95% CI 0.12 to 0.58; one RCT, n = 55; low-quality evidence), but the mean dyspareunia score was lower in this group (MD 0.33 points, 95% CI 0.62 to 0.04; low-quality evidence). The gestrinone group had lower rates of amenorrhoea (OR 0.04, 95% CI 0.01 to 0.38; one RCT, n = 49; low-quality evidence) and hot flushes (OR 0.20, 95% CI 0.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd009881.pub2

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 32

  1. Bromham, 1995, A multicentre comparative study of gestrinone and danazol in the treatment of endometriosis, Journal of Obstetrics and Gynaecology, 15, 188, 10.3109/01443619509015498 · DOI · Paper page
  2. Bromham, 1995, Updating the clinical experience in endometriosis - the European perspective, British Journal of Obstetrics and Gynaecology, 102 Suppl 12, 12, 10.1111/j.1471-0528.1995.tb09160.x · DOI
  3. Carbonell, 2012, Treatment with 5 mg or 25 mg of mifepristone daily for six months. A randomized double-blind study, Progresos de Obstetricia y Ginecologia, 55, 51
  4. Dawood, 1997, Clinical, endocrine, and metabolic effects of two doses of gestrinone in treatment of pelvic endometriosis, American Journal of Obstetrics and Gynecology, 176, 387, 10.1016/S0002-9378(97)70504-0 · DOI
  5. Fedele, 1989, Gestrinone versus danazol in the treatment of endometriosis, Fertility and Sterility, 51, 781, 10.1016/S0015-0282(16)60666-0 · DOI
  6. Gestrinone Italian Study Group, 1996, Gestrinone versus a gonadotropin releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: a multicenter, randomised, double-blind study, Fertility and Sterility, 66, 911, 10.1016/S0015-0282(16)58682-8 · DOI
  7. Hornstein, 1990, A randomised, double-blind prospective trial of two doses of gestrinone in the treatment of endometriosis, Fertility and Sterility, 53, 237, 10.1016/S0015-0282(16)53273-7 · DOI
  8. Spitz, 2009, Clinical utility of progesterone receptor modulators and their effect on the endometrium, Current Opinion in Obstetrics and Gynecology, 21, 318, 10.1097/GCO.0b013e32832e07e8 · DOI · Paper page
  9. Spitz, 2009, Progesterone receptor modulators in endometriosis: a new therapeutic option
  10. Worthington, 1993, A randomized comparative study of the metabolic effects of two regimens of gestrinone in the treatment of endometriosis, Fertility and Sterility, 59, 522, 10.1016/S0015-0282(16)55793-8 · DOI
  11. Kettel, 1998, Preliminary report on the treatment of endometriosis with low dose mifepristone (RU 486), American Journal of Obstetrics and Gynecology, 178, 1151, 10.1016/S0002-9378(98)70316-3 · DOI
  12. Mettler, 1984, Three-step therapy of genital endometriosis in cases of human infertility with lynestrenol, danazol or gestrinone administration in the second step, 33
  13. Nieto, 1996, Long term follow-up of endometriosis after two different therapies (gestrinone and buserelin), Clinical & Experimental Obstetrics and Gynecology, 23, 199
  14. Noble, 1980, Treatment of endometriosis: a study of medical management, British Journal of Obstetrics and Gynaecology, 87, 726, 10.1111/j.1471-0528.1980.tb04607.x · DOI
  15. Thomas, 1987, Impact of gestrinone on the course of asymptomatic endometriosis, British Medical Journal, 294, 272, 10.1136/bmj.294.6567.272 · DOI · Paper page
  16. Yang, 2006, Comparative study of Yiweining and gestrinone for post-operational treatment of stage 3 endometriosis, Chinese Journal of Integrative Medicine, 12, 218, 10.1007/BF02836527 · DOI
  17. Zhang, 2016, Effect of mifepristone in the different treatments of endometriosis, Clinical & Experimental Obstetrics and Gynecology, 43, 350, 10.12891/ceog2086.2016 · DOI
  18. Berek, 2007, Endometriosis
  19. Bouchard, 2011, Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety, Fertility and Sterility, 96, 1175, 10.1016/j.fertnstert.2011.08.021 · DOI · Paper page
  20. Brenner, 2002, Anti-proliferative effects of progesterone antagonists in the primate endometrium: a potential role for the androgen receptor, Reproduction, 124, 167, 10.1530/rep.0.1240167 · DOI
  21. Brenner, 2005, Progesterone receptor antagonists and the endometrial antiproliferative effect, Seminars in Reproductive Medicine, 23, 74, 10.1055/s-2005-864035 · DOI
  22. Brown, 2002, Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days, Journal of Clinical Endocrinology and Metabolism, 87, 63, 10.1210/jcem.87.1.8140 · DOI
  23. Eskenazi, 1997, Epidemiology of endometriosis, Obstetrics and Gynecology Clinics of North America, 24, 235, 10.1016/S0889-8545(05)70302-8 · DOI · Paper page
  24. Goldstein, 1980, Laparoscopy in the diagnosis and management of pelvic pain in adolescents, Journal of Reproductive Medicine, 24, 251
  25. Koide, 1998, Mifepristone: auxiliary therapeutic use in cancer and related disorders, Journal of Reproductive Medicine, 43, 551
  26. Li, 2016, Current progresses and trends in the development of progesterone receptor modulators, Current Medicinal Chemistry, 23, 2507, 10.2174/0929867323666160428105310 · DOI
  27. Narvekar, 2004, Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor, Journal of Clinical Endocrinology & Metabolism, 89, 2491, 10.1210/jc.2003-031945 · DOI · Paper page
  28. Neulen, 1996, Non-competitive anti-oestrogenic actions of progesterone antagonists in primate endometrium: enhancement of oestrogen and progesterone receptors with blockade of post-receptor proliferative mechanisms, Human Reproduction, 11, 1533, 10.1093/oxfordjournals.humrep.a019433 · DOI
  29. Spitz, 2003, Progesterone antagonists and progesterone receptor modulators: an overview, Steroids, 68, 981, 10.1016/j.steroids.2003.08.007 · DOI
  30. Tosti, 2016, Hormonal therapy for endometriosis: from molecular research to bedside, European Journal of Obstetrics & Gynecology and Reproductive Biology, 5, 32
  31. Vercellini, 2014, Endometriosis: pathogenesis and treatment, Nature Reviews Endocrinology, 10, 261, 10.1038/nrendo.2013.255 · DOI · Paper page
  32. Williams, 2007, The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata, Human Reproduction, 22, 1696, 10.1093/humrep/dem026 · DOI · Paper page

Cited by

See all 61

Metadata

Authors
Fu, J., Song, H., Zhou, M., Zhu, H., Wang, Y., Chen, H., & Huang, W.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2017-07-25
Volume
2017
Issue
7
Pages
CD009881-CD009881
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W2736569292
Cited by
61
References
8
FWCI
4.59
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Progesterone receptor modulators for endometriosis. https://app.cochat.ai/papers/10.1002/14651858.cd009881.pub2
The paper
Fu, J., Song, H., Zhou, M., Zhu, H., Wang, Y., Chen, H., & Huang, W. (2017). Progesterone receptor modulators for endometriosis. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd009881.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.